AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by investment analysts at Jefferies Group in a research report issued to clients and investors on Friday. They currently have a GBX 6,000 ($73.13) target price on the biopharmaceutical company’s stock. Jefferies Group’s price target points to a potential upside of 30.02% from the stock’s previous close.
A number of other analysts have also recently weighed in on AZN. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 5,600 ($68.25) price target on shares of AstraZeneca plc in a research report on Thursday, June 30th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research report on Friday, July 1st. BNP Paribas reiterated an “outperform” rating and issued a GBX 5,000 ($60.94) price target on shares of AstraZeneca plc in a research report on Sunday, July 3rd. Credit Suisse Group AG restated an “underperform” rating and set a GBX 4,000 ($48.75) target price on shares of AstraZeneca plc in a report on Monday, July 4th. Finally, Morgan Stanley restated an “overweight” rating and set a GBX 5,000 ($60.94) target price on shares of AstraZeneca plc in a report on Monday, July 11th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 4,966.24 ($60.53).
Shares of AstraZeneca plc (LON:AZN) opened at 4614.50 on Friday. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm’s 50-day moving average price is GBX 4,982.30 and its 200 day moving average price is GBX 4,531.79. The firm’s market cap is GBX 58.37 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.